Audit: QRS - Statins for Health & Longevity

Audit conducted on 23/08/2026 02:47 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells trace to ER lines 392/394/398; time cells to line 441; benefits/risks to the ER tier headings; monitoring rows to the ER biomarker table (lines 471–482); gates to lines 329–356.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Costs are real, mostly modest and measurable” mirrors ER line 513; “No target; track change from baseline” mirrors ER line 482; “Proposed basis of muscle and fatigue complaints” keeps the ER’s hedged framing.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain absolute; “the gain over a few years is small when arteries are demonstrably clean” preserves the ER’s own hedge (line 511).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Fibrates and red yeast rice sit under Contraindications because the ER names both “absolute contraindication” (lines 329, 341); no Benefit- or Risk-Modifying Factor is surfaced anywhere.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The only brand name is “Lopid”, carried verbatim from the ER bold label at line 329; no PMIDs, NCT IDs, author names or expert names appear.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Same measured, non-promotional register; the ER’s balancing of a strong benefit signal against measurable costs is carried into At-A-Glance.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Targets, cadence and decision gates give the reader actionable structure without exhortation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as fact and target, not as instruction to the reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring cadence and qualitative items are noun phrases describing practice, not directives.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “should”, “recommend” or “advise” anywhere in the body content.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms present are all carried from the ER and are load-bearing (ApoB, hsCRP, Lp(a)); no avoidable jargon added.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lines are semicolon-joined heading lists; monitoring cells are truncated to essentials; gate items strip all ER rationale.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets (ApoB <80/<60, HbA1c 5.0–5.4%, fasting glucose 75–90) are optimizer-grade, not conventional-lab, ranges.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	A twelve-marker panel including Lp(a) and coenzyme Q10, plus a six-item qualitative log, assumes high willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Nothing is pitched at conventional reference ranges or minimal-effort monitoring.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	“Blunted aerobic training adaptation” is retained at Medium and exercise tolerance appears in Qualitative Assessment — the audience-specific cost the ER flags at lines 279 and 460.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Transaminase”, “myopathy”, “rhabdomyolysis”, “adaptation” used throughout; no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified verbatim at lines 446, 492, 540, 623, 651, 839 (headings), 571 and 589 (gates), 544/550/556/562 and 627/633/636/642 (tiers), 655–657 (column headers).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	76 unique data-qrs-var spans present, covering every variable named in the checklist (page_title, header_, at_a_glance, action_1–3, time_1–3, benefits_, stop_items, caution_items, risks_*, marker_1–12, monitoring_cadence, qualitative_item_1–6); none duplicated, none missing.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable template spans (website="evidence_review", website="audit", website="full_review") are untouched and empty as delivered.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Typical starting doses”, “Single versus split dosing”, “Best time of day” are the ER bold labels verbatim (lines 392, 398, 394); gate items reuse the ER bold labels (“Fibrates (triglyceride-lowering drugs), especially gemfibrozil (Lopid)”, “Colchicine”, “Warfarin”).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	All twelve monitoring marker names match the ER Biomarker column exactly; protocol labels are verbatim; the time-cell labels are the only derived labels and are required because the ER carries the three aspects inside a single “Time to effect” bullet.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji anywhere; the ER’s tier squares and ⚠️ Conflicted markers are stripped, tiering conveyed by bold “High/Medium/Low/Speculative” plus CSS.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the minimum consistent with the mandatory-completeness items (14.2, 15.2, 8.2, 9.2): tier lines are single sentences, monitoring “Target”/”Why” cells are trimmed to four to six words, gate items carry no rationale.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; it is the first node after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text on line 2 sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It is a plain HTML comment; no element echoes any of its values except the two the header legitimately renders (creation date, model name).
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon so quoting is required.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: statins_2026-0823-0001_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0823-0210, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version, no qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version only.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: statins_2026-0823-0001_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eleven keys; only the colon-bearing duration is quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Statins for Health & Longevity - Quick Reference Sheet; ER canonical_topic is “Statins for Health & Longevity” and the ampersand is entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Statins for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/23/2026, correctly derived from qrs_creation_date: 2026-0823-0210.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line and prompt version are not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All four clauses map onto ER Conclusion paragraphs 1–2 (lines 511, 513): mechanism, outcome set, who gains most versus least, and the cost profile.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words (script-counted), within the limit.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“block the liver enzyme that makes cholesterol… strip artery-damaging particles” = line 511 clause 1; “heart attacks, strokes and death from any cause” = line 511 clause 2; the plaque/particle/inflammation/inherited list and the “demonstrably clean” hedge = line 511 clauses 4–5; “costs are real but mostly modest and measurable” = line 513.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms at all; “artery-damaging particles” replaces ApoB/LDL, “inherited high cholesterol” replaces familial hypercholesterolemia, “plaque” and “particle counts” are lay-legible.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No RR, HR, OR, NNT, confidence intervals or percentages.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Six items from “Populations who should avoid Statins” (ER lines 351–356) plus the two bullets the ER calls “absolute contraindication” (lines 329, 341).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER contraindications are present; none invented.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 574–584: eight discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER trailing clauses all stripped: the fetal-development rationale (line 351), “an absolute contraindication to rechallenge with any statin” (line 353), “where randomized trials show no benefit…” (line 354), “where trials show no outcome benefit” (line 355), and the glucuronidation/OATP1B1 mechanism (line 329).
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“above 3× the upper limit of normal” (threshold) and “(New York Heart Association Class III–IV)” (clinical staging) are both retained; “Fibrates (triglyceride-lowering drugs), especially gemfibrozil (Lopid)” keeps the ER’s parenthetical gloss and named example.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, correctly, because the ER identifies eight such conditions.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map one-to-one onto ER bullets at lines 331, 333, 335, 337, 339, 343, 345, 347.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Fibrates (line 329) and red yeast rice (line 341) are correctly excluded here and carried in the Contraindications gate instead; the remaining eight ER interaction bullets are all present.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 592–613: eight discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “caution; …” rationale and every “Mitigation: …” clause is stripped, as are the psyllium citation (line 343) and the dose-cap detail (line 333); no em-dash or en-dash trailing content survives.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example list is retained and trimmed rather than dropped: CYP3A4 inhibitors keep five of seven names, cardiac drugs four of six, OTC agents keeps the “niacin above 1 g” threshold and the rosuvastatin/antacid pairing, and the two supplement lists and the “other interventions” list are all preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation appears inside the parentheses of the ER’s interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, correctly, because the ER identifies eight such interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells come from the ER Therapeutic Protocol section (lines 392, 398, 394).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Starting dose, dosing frequency and timing are the three bullets in that section that state what is actually done; the remaining bullets describe competing philosophies, pharmacokinetics and patient-selection considerations rather than executable steps.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER mentions more than three actionable aspects, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: labels verbatim from the ER bold labels, values carrying the ER doses/schedules, subs carrying the ER’s secondary agents, four-to-six week reassessment, salvage schedule and per-agent timing.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Clinical events (years), LDL/ApoB fall (1–2 weeks) and lipid steady state (4–6 weeks) are exactly the three horizons the ER states at line 441.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Clinical events first (tied to the two largest High-tier benefits, event reduction and all-cause mortality), then the two lipid horizons tied to the third High-tier benefit, ordered by onset.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER states three distinct time-to-effect aspects, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated and traceable to ER line 441; no placeholder text remains.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (line 441), so removal does not apply.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed item is an ER Expected Benefits heading, in ER order within each tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 542, 548, 554, 560, each carrying its tier’s items.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details. No mechanistic explanations, etc. Just the key fact.	🟢	Items are bare heading text; none of the ER’s Magnitude lines (RR 0.78, RR 0.92, OR 0.80, HR 0.78, the 26-trial/170,000-participant detail) is carried across.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven items are ER Potential Risks & Side Effects headings, tier by tier and in ER order.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 625, 632, 635, 641, each carrying its tier’s items.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details. No mechanistic explanations, etc. Just the key fact.	🟢	Bare heading text only; the ER’s rate ratios, nocebo ratio, incidence-per-100,000 figures and the VO₂max numbers are all absent, as are the “⚠️ Conflicted” qualifiers.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER Monitoring Protocol & Defining Success biomarker table (lines 469–482), condensing “Optimal Functional Range” into Target and “Why Measure It?” into Why.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All twelve are present and in ER order: ApoB, LDL cholesterol, Lp(a), hsCRP, HbA1c, fasting glucose, ALT and AST, creatine kinase, eGFR and creatinine, thyroid-stimulating hormone, vitamin D (25-hydroxy), coenzyme Q10. Targets match the ER exactly, including the dual ApoB/LDL cut-offs and the “no established target” note for coenzyme Q10.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 829–833 carry the full ER cadence from line 467: baseline panel pre-dose, lipids with ApoB at 6–8 weeks and after dose changes, full panel with HbA1c and liver enzymes at 6 months, then annually, with creatine kinase on symptoms rather than on schedule.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s “Qualitative markers worth tracking alongside the labs” list (lines 486–491).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Six of six present and in ER order: muscle symptoms with onset date and distribution, exercise tolerance and recovery, cognitive clarity, energy and fatigue in the first eight weeks, sleep quality after agent switches, and long-term sustainability.

Issues 23/08/2026 02:47

Pass rate 100.00%. No issues found.

Issues 23/08/2026 02:41

1. 1.3 — Contraindication qualifiers dropped: The QRS broadens two gates relative to the ER: “unexplained persistent transaminase elevation” (ER line 352) is rendered as “persistent transaminase elevation” (QRS line 576), and “Documented hypersensitivity to the specific agent” (ER line 356) is rendered as “Hypersensitivity to the specific agent” (QRS line 582).

Fixes 23/08/2026 02:41

1. 1.3 — Contraindication qualifiers restored: Restored the two ER qualifiers dropped from the Contraindications gate — “persistent transaminase elevation” is now “unexplained persistent transaminase elevation”, and “Hypersensitivity to the specific agent” is now “Documented hypersensitivity to the specific agent”.

Issues 23/08/2026 02:34

1. 4.5 — Sheet exceeds the one-page budget: The Monitoring Target and Why cells (lines 665–830), the six Qualitative Assessment items (lines 848–880) and the Key Interactions parenthetical drug lists (lines 593–615) reproduce the ER text at full length rather than condensed, so at 9–9.5 pt the Monitoring table runs about two wrapped lines per row across twelve rows and the gate columns exceed seventeen wrapped lines, carrying the sheet past a single A4 page.

Fixes 23/08/2026 02:34

1. 4.5 — Monitoring Why column condensed: All twelve marker_#_why cells were shortened from full ER sentences to single-line phrases (e.g., “Direct count of artery-damaging particles; the primary treatment target” → “Particle count; the primary target”; “Residual inflammatory risk, which outpredicts residual cholesterol for mortality” → “Residual inflammatory risk”).
2. 4.5 — Monitoring Target column condensed: The four multi-line targets were tightened (e.g., “<80 mg/dL general; <60 mg/dL with established plaque” → “<80 mg/dL; <60 with plaque”; “No established target range; track change from own pre-treatment value” → “No target; track change from baseline”), with all thresholds preserved.
3. 4.5 — Qualitative items stripped of rationale: Items 1, 2, 3 and 6 lost their trailing explanatory clauses (e.g., “…, given how commonly these are attributed to statins” and “…, since intermittent use forfeits most of the benefit”); all six markers remain listed.
4. 4.5 — Key Interactions drug lists trimmed: Example lists were shortened where the ER carries redundant members (ketoconazole/cobicistat, ranolazine/digoxin, “omeprazole and other”, “psyllium and other soluble fibre”, “intensive resistance or endurance training” → “intensive training”), keeping every named class and the “niacin above 1 g” threshold.
5. 4.5 — Contraindications tightened: “Pregnancy, active attempts to conceive, and breastfeeding” → “Pregnancy, conception attempts, breastfeeding”, “above three times the upper limit of normal” → “above 3× the upper limit of normal”, and “Documented hypersensitivity…” → “Hypersensitivity…”.
6. 4.5 — Protocol and Time-to-Effect subs shortened: The three action_#_sub and three time_#_sub cells were compressed (e.g., “Reduction in clinical events accrues over years, not months.” → “Accrues over years, not months.”), each dropping one wrapped line.
7. 4.5 — Monitoring cadence compressed: The cadence sentence was tightened to “…Lipids with ApoB at 6–8 weeks and after any dose change; full panel with HbA1c and liver enzymes at 6 months, then annually once stable. Creatine kinase on symptoms, not on schedule.”

Issues 23/08/2026 02:26

1. 1.1 — Time-to-effect claim altered: time_2_sub (QRS line 518) says LDL cholesterol and ApoB “begin falling within one to two weeks of starting”, whereas the ER (line 441) states they “fall within one to two weeks”; the QRS wording reduces a completed fall to a mere onset and is not literally supported.

Fixes 23/08/2026 02:26

1. 1.1 — Time-to-effect claim restored: Changed time_2_sub from “LDL cholesterol and ApoB begin falling within one to two weeks of starting” to “LDL cholesterol and ApoB fall within one to two weeks of starting”, matching the ER’s assertion at line 441.

Issues 23/08/2026 02:17

1. 1.3 — At-A-Glance drops horizon qualifier: [at_a_glance] (line 437) says “the gain is small when arteries are demonstrably clean”, omitting the ER’s “over a few years” (ER line 511); the ER treats that horizon as load-bearing and flags longer exposure as untested (ER line 165), so the unqualified form broadens the claim.

Fixes 23/08/2026 02:17

1. 1.3 — At-A-Glance horizon qualifier restored: [at_a_glance] now reads “the gain over a few years is small when arteries are demonstrably clean”, restoring the ER’s horizon qualifier (ER line 511). “for anyone” and “but” were trimmed to keep the passage at 60 words for item 7.2.